Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report)’s share price passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.03 and traded as high as $0.06. Mateon Therapeutics shares last traded at $0.06, with a volume of 161,591 shares.
Mateon Therapeutics Stock Down 2.8 %
The stock has a 50 day moving average of $0.04 and a 200 day moving average of $0.03.
Mateon Therapeutics Company Profile
Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.
See Also
- Five stocks we like better than Mateon Therapeutics
- Learn Technical Analysis Skills to Master the Stock Market
- FedEx Delivers Another Crushing Blow to Its Stock Price
- Investing In Preferred Stock vs. Common Stock
- Analysts Stay Bullish on Rocket Lab as Signs of a Bottom Emerge
- The 3 Best Fintech Stocks to Buy Now
- Micron Stock Will Retest All-Time Highs This Year
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
